This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (134)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal

A Systematic Review of the Literature

Wee Shian Chan, MD, FRCPC; Sonia Anand, MD, FRCPC; Jeffrey S. Ginsberg, MD, FRCPC

Arch Intern Med. 2000;160:191-196.

Background  The management of women with prosthetic heart valves during pregnancy poses a particular challenge as there are no available controlled clinical trials to provide guidelines for effective antithrombotic therapy. Oral anticoagulants such as warfarin sodium cause fetal embryopathy; subcutaneous administration of heparin sodium has been reported to be ineffective in preventing thromboembolic complications.

Objective  To identify the risks of maternal and fetal complications in women with mechanical heart valves treated with different anticoagulation regimens during pregnancy.

Methods  We performed a systematic review of the literature to determine pooled estimates of maternal and fetal risks associated with the 3 commonly used approaches: (1) oral anticoagulants (OA) throughout pregnancy, (2) replacing OA with heparin in the first trimester (from 6-12 weeks' gestation), and (3) heparin use throughout pregnancy. Fetal outcomes included spontaneous abortions and fetopathic effects, and maternal outcomes were major bleeding, thromboembolic complications, and death.

Results  The use of OA throughout pregnancy is associated with warfarin embryopathy in 6.4% (95% confidence interval [CI], 4.6%-8.9%) of livebirths. The substitution of heparin at or prior to 6 weeks, and continued until 12 weeks, eliminated this risk. Overall risks for fetal wastage (spontaneous abortion, stillbirths, and neonatal deaths) were similar in women treated with OA throughout, compared with women treated with heparin in the first trimester. Maternal mortality was 2.9% (95% CI, 1.9%-4.2%). Major bleeding events occurred in 2.5% (95% CI, 1.7%-3.5%) of all pregnancies, most at the time of delivery. The regimen associated with the lowest risk of valve thrombosis (3.9%; 95% CI, 2.9-5.9%) was the use of OA throughout; using heparin only between 6 and 12 weeks' gestation was associated with an increased risk of valve thrombosis (9.2%; 95% CI, 5.9%-13.9%).

Conclusions  Thromboembolic prophylaxis of women with mechanical heart valves during pregnancy is best achieved with OA; however, this increases the risk of fetal embryopathy. Substituting OA with heparin between 6 and 12 weeks reduces the risk of fetopathic effects, but with an increased risk of thromboembolic complications. The use of low-dose heparin is definitely inadequate; the use of adjusted-dose heparin warrants aggressive monitoring and appropriate dose adjustment. Large prospective trials to determine the best regimen for these women are needed.

From the Departments of Medicine, Women's College Hospital, Toronto (Dr Chan), and McMaster University, Hamilton (Drs Anand and Ginsberg), Ontario.

RELATED ARTICLE

Archives of Internal Medicine Reader's Choice: Continuing Medical Education
Arch Intern Med. 2000;160(2):245-246.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Venous Thromboembolism, Thrombophilia, Antithrombotic Therapy, and Pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Bates et al.
Chest 2008;133:844S-886S.
ABSTRACT | FULL TEXT  

Outpatient-Based Primary and Secondary Thromboprophylaxis With Low-Molecular-Weight Heparin
Spyropoulos
CLIN APPL THROMB HEMOST 2008;14:63-74.
ABSTRACT  

Anticoagulation in Pregnancy with Mechanical Heart Valves: 10-Year Experience
Akhtar et al.
Asian Cardiovasc. Thorac. Ann. 2007;15:497-501.
ABSTRACT | FULL TEXT  

Management of Venous Thromboembolism
Bhaskar
ANN INTERN MED 2007;147:519-520.
FULL TEXT  

Pregnancy in women with valvular heart disease
Stout and Otto
Heart 2007;93:552-558.
ABSTRACT | FULL TEXT  

Cardiac disease in pregnancy. Part 2: acquired heart disease
Gelson et al.
The Obstetrician and Gynaecologist 2007;9:83-87.
ABSTRACT | FULL TEXT  

Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology
Authors/Task Force Members et al.
Eur Heart J 2007;0:ehl428v1-39.
FULL TEXT  

A clinical approach to the management of thrombosis in obstetrics. Part 2: diagnosis and treatment of venous thromboembolism
Asghar and Bowman
The Obstetrician and Gynaecologist 2007;9:3-8.
ABSTRACT | FULL TEXT  

Management of Pregnant Women with Thrombophilia or a History of Venous Thromboembolism
Bates
ASH Education Book 2007;2007:143-150.
ABSTRACT | FULL TEXT  

ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) Developed in Collaboration With the Society of Cardiovascular Anesthesiologists Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons
Bonow et al.
J Am Coll Cardiol 2006;48:e1-e148.
FULL TEXT  

Report of the National Heart, Lung, and Blood Institute Working Group on Research in Adult Congenital Heart Disease
Williams et al.
J Am Coll Cardiol 2006;47:701-707.
ABSTRACT | FULL TEXT  

Pregnancy and congenital heart disease
Uebing et al.
BMJ 2006;332:401-406.
FULL TEXT  

Risk of Osteoporotic Fracture in Elderly Patients Taking Warfarin: Results From the National Registry of Atrial Fibrillation 2
Gage et al.
Arch Intern Med 2006;166:241-246.
ABSTRACT | FULL TEXT  

Recommendations for the management of patients after heart valve surgery
Butchart et al.
Eur Heart J 2005;26:2463-2471.
ABSTRACT | FULL TEXT  

Valvular Heart Disease and Pregnancy: Part II: Prosthetic Valves
Elkayam and Bitar
J Am Coll Cardiol 2005;46:403-410.
ABSTRACT | FULL TEXT  

Congenital heart disease in pregnancy
Head and Thorne
Postgrad. Med. J. 2005;81:292-298.
ABSTRACT | FULL TEXT  

Anticoagulation in Patients with Mechanical Valves During Pregnancy
Geelani et al.
Asian Cardiovasc. Thorac. Ann. 2005;13:30-33.
ABSTRACT | FULL TEXT  

The Ross II Procedure: Pulmonary Autograft in the Mitral Position
Athanasiou et al.
Ann. Thorac. Surg. 2004;78:1489-1495.
ABSTRACT | FULL TEXT  

Use of Antithrombotic Agents During Pregnancy: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Bates et al.
Chest 2004;126:627S-644S.
ABSTRACT | FULL TEXT  

Fallot's tetralogy and pregnancy: Prognostication and prophesy
Child
J Am Coll Cardiol 2004;44:181-183.
FULL TEXT  

The mitral pulmonary autograft: assessment at midterm
Kabbani et al.
Ann. Thorac. Surg. 2004;78:60-65.
ABSTRACT | FULL TEXT  

Management and follow up of prosthetic heart valves
Seiler
Heart 2004;90:818-824.
FULL TEXT  

Anticoagulation in Pregnant Women With Prosthetic Heart Valves
Elkayam et al.
J CARDIOVASC PHARMACOL THER 2004;9:107-115.
ABSTRACT  

Prosthetic Heart Valves and Pregnancy * Response
McLintock et al.
Circulation 2003;108 :e159-e160.
FULL TEXT  

Valvular Heart Disease in Pregnancy
Reimold and Rutherford
NEJM 2003;349:52-59.
FULL TEXT  

Anticoagulation of Pregnant Women With Mechanical Heart Valves
Ginsberg et al.
Arch Intern Med 2003;163:694-698.
ABSTRACT | FULL TEXT  

Thrombotic Disorders: Diagnosis and Treatment
Schafer et al.
ASH Education Book 2003;2003:520-539.
ABSTRACT | FULL TEXT  

Effect of Oral Anticoagulant During Pregnancy With Prosthetic Heart Valve
Srivastava et al.
Asian Cardiovasc. Thorac. Ann. 2002;10:306-309.
ABSTRACT | FULL TEXT  

Pregnancy and mechanical heart valves replacement; dilemma of anticoagulation
Al-Lawati et al.
Eur. J. Cardiothorac. Surg. 2002;22:223-227.
ABSTRACT | FULL TEXT  

Thrombin generation and its inhibition: a review of the scientific basis and mechanism of action of anticoagulant therapies
Walker and Royston
Br J Anaesth 2002;88:848-863.
ABSTRACT | FULL TEXT  

The Ross procedure is the procedure of choice for congenital aortic valve disease
Al-Halees et al.
J. Thorac. Cardiovasc. Surg. 2002;123:437-442.
ABSTRACT | FULL TEXT  

Risk of Warfarin During Pregnancy With Mechanical Valve Prostheses
Cotrufo et al.
Obstet Gynecol 2002;99:35-40.
ABSTRACT | FULL TEXT  

Health technology assessment of oral anticoagulation following heart valve replacement
Perleth and Busse
Eur Heart J Suppl 2001;3:Q60-Q64.
ABSTRACT  

Is it Time to Look for an Alternative?
Kabbani
Asian Cardiovasc. Thorac. Ann. 2001;9:79-81.
FULL TEXT  

Anticoagulation Therapy
Ginsberg et al.
ASH Education Book 2001;2001:339-357.
ABSTRACT | FULL TEXT  

Use of Antithrombotic Agents During Pregnancy
Ginsberg et al.
Chest 2001;119:122S-131S.
FULL TEXT  

Anticoagulation and Mechanical Heart Valves in Pregnancy
JWatch General 2000;2000:5-5.
FULL TEXT